Cellceutix Corp. (CTIX.OB) reported that it has been conducting meetings with manufacturers to synthesize and formulate its lead psoriasis drug, Prurisol, for a Phase 2/3 clinical trial.
Cellceutix said the U.S. Food and Drug Administration recently told the company that an application for a 505(b)(2) designation for Prurisol would be an acceptable approach; allowing the Company to advance Prurisol immediately into advanced stages of clinical trials.
For comments and feedback: editorial@rttnews.com